Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 2/20 | 0.40 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20621865 | 0.79 | DHODH (0.56) | KMT2AMAPT | |
| SCHEMBL29454721 | 0.79 | DHODH (0.56) | KMT2AMAPT | |
| SCHEMBL4831443 | 0.74 | BCHE (0.46) | CCNCCDK8BCHEACHEKDM4C | |
| SCHEMBL30824201 | 0.72 | MDM2 (0.47) | BCHEPOLBKMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL27713387 | 0.71 | CA12 (0.39) | CCNCCDK8BCHEACHEKDM4C | |
| SCHEMBL20599878 | 0.71 | MEN1 (0.39) | KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL10277361 | 0.70 | GAA (0.58) | KMT2AL3MBTL1TP53MAPT | |
| SCHEMBL30824242 | 0.70 | GAA (0.58) | KMT2AL3MBTL1TP53MAPT | |
| SCHEMBL20599776 | 0.70 | GSK3B (0.39) | KDM4CKMT2AMAPT | |
| SCHEMBL16305298 | 0.69 | CA1 (0.46) | CCNCCDK8BCHEACHEKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | disclosed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | disclosed |
| EP-3615527-B1 | NEW AZAQUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-4255911-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-11485733-B2 | Azaquinoline derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2022117783-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| EP-3980414-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | Elanco Tiergesundheit AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | disclosed |
| WO-2020247747-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-12-10 | — | — | WO | disclosed |
| US-20200131175-A1 | NEW AZAQUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| EP-3615527-A1 | NEW AZAQUINOLINE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| WO-2019002132-A1 | NEW AZAQUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131175-A1 | NEW AZAQUINOLINE DERIVATIVES | RECQL, H1-5, CHRM1 | CCNC 707/4885CDK8 1717/4885BCHE 458/4885 |
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | TBXA2R, PIGS, CYCS | CCNC 2033/4885CDK8 2893/4885BCHE 140/4885 |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, TNNI3 | CCNC 1025/4885CDK8 2589/4885BCHE 271/4885 |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | TBXA2R, PIGS, CYCS | CCNC 2033/4885CDK8 2893/4885BCHE 140/4885 |
| US-11485733-B2 | Azaquinoline derivatives | RECQL, H1-5, H1-3 | CCNC 893/4885CDK8 2078/4885BCHE 469/4885 |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | CYCS, FABP3, TNNI3 | CCNC 948/4885CDK8 2375/4885BCHE 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.